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ABSTRAcT
Bisphosphonates offer a significant improvement in the quality of life for cancer patients; these potent inhibitors of 
bone resorption have been shown to markedly reduce the morbidity frequently resulting from bone metastases. Despite 
the success of bisphosphonates as therapeutic agents, however, toxicity in the form of osteonecrosis of the jaw (ONJ) is 
a rare complication whose incidence rate has climbed in recent years.  ONJ is defined as an unexpected development of 
necrotic bone in the oral cavity, and is commonly associated with administration of the bisphosphonates Pamidronate 
and Zoledronate.  Clinical features include local pain, soft-tissue swelling, and/or loose teeth; ONJ is also often corre-
lated with previous dental procedures, such as tooth extractions, during biphosphonate therapy.  Although additional 
risk factors--such as corticosteroids, chemotherapy, radiotherapy, trauma or infection—exhibit etiological associations 
with ONJ, the real pathobiology has not yet been fully elucidated.  Here we report our findings on all 2005 OJN cases 
presented at our institution resulting from bone metastatic prostate cancer treated with zoledronic acid. The incidence 
of ONJ is nearly 3% (3 out of 104) in these patients.
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INTRODUcTION
The skeleton is the most common site to be affected by 
metastatic cancers. Multiple myeloma, breast, and prostate 
cancers harbor the highest prevalence of bone metastases. 
While overall survival and lifespan of  these patients is 
relatively long, they unfortunately carry a considerable 
morbidity due to skeletal-related events (SRE). These SRE 
include bone pain, general weakness/fatigue, impaired 
mobility, pathological fractures, spinal cord compression, 
and hypercalcemia, all of which contribute to a decreased 
quality of life. (1)
Metastases to the bone are common and difficult compli-
cations of prostate cancer; 80% of patients with advanced 
prostate cancer present with bone metastases. Median survi-
val in patients with limited bone disease is over 53 months, 30 
months in patients with visceral disease, and only 12 months 
in those with poor performance status and visceral disease. 
The rapid and severe manner in which bone metastases 
descend upon a patient’s health commands attention for the 
clinical management of treatment options. (2, 3)
Palliative bone-targeted therapies are designed to prevent 
bone-pain, disability from cord compression, and pathologi-
cal fractures. There are several approaches to the treatment 
of  bone metastases: anticancer (endocrine or cytotoxic) 
treatment, external beam radiotherapy, palliative surgery, 
analgesia, and bisphosphonates. (1) 
Bisphosphonates have emerged as an integral tool in the 
prevention of SRE in metastatic cancer patients.  These com-
pounds have a common phosphorus-carbon-phosphorus 
backbone and an affinity for hydroxyapatite crystals located 
E352
Med Oral Patol Oral Cir Bucal 2007;12:E351-6.                                                                                                                                                                                    Osteonecrosis of the jaw and zoledronic acid                                                             Med Oral Patol Oral Cir Bucal 2007;12:E351-6.                                                                                                                                                                                      Osteonecrosis of the jaw and zoledronic acid
specifically in areas of dynamic bone resorption and rege-
neration. Through this targeted activity, bisphosphonates 
inhibit normal and pathological osteoclast-mediated bone 
resorption by multiple mechanisms; they reduce the number 
and activity of the osteoclasts by modifying their adhesion, 
recruitment, cytoskeletal arrangement, differentiation, and 
survival, and can also act thought several mechanisms on 
osteoblasts and macrophages (4) Prostate cancer bone me-
tastases differ from bone metastases associated with most 
other cancers because the former are usually sclerotic or 
osteoblastic. Osteoblastic metastases from prostate cancer 
increase osteoblast number and activity, bone volume, and 
bone mineralization rate; however, biochemical and micros-
copic evidence suggest that prostate cancer bone metastases, 
as in myelomas and breast cancers, have an osteolytic com-
ponent. Furthermore, osteoclast number and activity are 
increased in prostate cancer-related osteoblastic metastases 
as well as in adjacent and distant healthy bone. (3, 5)
The overall effect of bisphosphonate treatment is thus the 
collective reduction of excessive bone turnover, resulting in 
preservation of structure and mineralization of the bone. 
Due to these findings, bisphosphonates have become the 
standard treatment for preventing skeletal complications 
in cancer patients with bone metastases. (3)
Zoledronic acid is the only bisphosphonate that has shown 
a statistically significant reduction in SRE, resulting in du-
rable palliation of bone pain in prostate cancer metastases. 
(2) Although the optimal treatment duration of zoledronic 
acid therapy has not yet been established, available evidence 
suggests that bone morbidity is decreased as long as the 
patient undergoes zoledronic acid treatment. On the basis 
of clinical practice guidelines for breast cancer and multiple 
myeloma (5), zoledronic acid treatment should continue 
until the appearance of treatment-related adverse events 
or until a substantial decline in patient performance status 
is observed. (6)
Adverse effects associated with the use of bisphosphonates 
are rare and consist of pyrexia, renal function impairment, 
and hypocalcemia. Recently, a new complication associated 
with their use has been described: avascular osteonecrosis 
of the jaw (ONJ). (7)Here we describe three cases of ONJ 
in prostate cancer patients treated with zoledronic acid 
in a prospective surveillance report during 2005 at our 
hospital. 
cLINIcAL cASES
A summary of the clinical cases is shown in table 1. 
Case 1.
A 60-year-old man affected by diabetes mellitus and ische-
mic cardiopathy was diagnosed of prostatic adenocarcinoma 
in 2000. We  treated  him with complete androgen blockade 
(bicalutamide + triptoreline)  until serologic and retroperi-
toneal progression in October 2003. Retroperitoneal radio-
therapy was administrated, followed by a stramustine and 
triptoreline combination. He developed bone progression in 
December 2004. As the tumor became hormone refractory, 
he received chemotherapy and mensual zoledronic acid (4 
mg. in 15 minutes, every 4 weeks). Since then he has under-
gone three additional chemotherapy treatments. Zoledronic 
acid was administered every four weeks for a total of 14 
times. In December 2005 the patient presented dysesthesias 
of the jaw. Exploration of the oral cavity revealed halitosis, 
hypoesthesia of the inferior alveolar nerve, and soft-tissue 
swelling in the left hemiarch. An orthopantomography 
showed sequestrum formation related to osteonecrosis of 
the jaw (see figure 1). 
Case 2.
A 68-year-old man was diagnosed of prostatic adenocarci-
noma in 2002 with bone metastases. He received palliative 
radiotherapy on vertebral collapses (D5-D8 and L3-L4). 
We prescribed complete androgen blockade (bicalutamide 
+ gosereline) until the tumor became hormone refractory in 
September 2004. At this stage he was treated with chemothe-
rapy while maintaining a good performance status.  He then 
followed treatment with prednisone in monotherapy.  Due 
to maxillae teeth infections, he underwent dental extractions 
before ONJ diagnosis. Zoledronic acid was administrated for 
8 courses and stopped when dysesthesias of the jaw, halitosis 
and fall of teeth occurred. Exploration of the oral cavity 
revealed loose teeth in the jaw, bone exposure, and adjacent 
soft tissue abscess. We performed an orthopantomography 
as a complementary diagnostic test (see figure 2). 
Fig. 1. Orthopantomography of the ONJ developed in case 1 (left side).
Fig. 2. Orthopantomography of  the ONJ developed in case 2. (right 
side).
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Case 3
A 70-year-old man was diagnosed with prostate adenocarci-
noma in 1998. Radical intention radiotherapy was adminis-
trated, followed by maximum androgen blockade (flutamide 
+ triptoreline) until serologic and bone progression in July 
2003. He received four chemotherapy lines and 12 doses of 
zoledronic acid. Tooth extractions were performed during 
zoledronic therapy.  We interrupted biphosphonate adminis-
tration when pain and fall of teeth appeared. Exploration 
of the oral cavity revealed loose teeth in the mandible, bone 
exposure, and soft tissue swelling.  An orthopantomography 
and CT of the jaw confirmed ONJ (see figure 3 and 4).
DIScUSSION
The four types of intravenous bisphosphonates (clodronate, 
ibandronate, pamidronate and zoledronate) have shown 
therapeutic efficacy in the prevention of SRE related to the 
presence of bone metastases in breast cancer; (1) however, 
these drugs are not all effective for the treatment of bone 
metastases in prostate cancer. Several studies, which used 
pain due to bone metastases as the primary endpoint, failed 
to demonstrate a difference between clodronate and pami-
dronnate treatment versus the placebo. (8, 9)
Zoledronic acid is the only bisphosphonate that has demons-
trated a statistically significant reduction in SRE compared 
with placebo in patients with metastatic prostate cancer. As 
a result, it has become the standard treatment for this class 
of patients. (2)
Severe adverse effects associated with the use of intravenous 
biphosphonates are uncommon; the most frequently repor-
ted side effects include fever, acute systemic inflammatory 
reactions, ocular complications, nephrotoxicity, and/or 
electrolyte abnormalities such as hypocalcemia, hypophos-
phatemia and hypomagnesemia. (10) In our series, only 
a low level hypocalcemia and a limited renal impairment 
were recorded in one and two patients, respectively (see 
table 1). Recently, a novel complication associated with 
the use of bisphosphonates has been described, known as 
avascular osteonecrosis of the jaw (ONJ).  ONJ diagnosis is 
suspected in patients from the presence of such symptoms 
as pain, halitosis, soft-tissue swelling, gingival bleeding and 
infection, tooth loss, and/or dysesthesias of the jaw. (11-13) 
The typical presentation is a nonhealing extraction socket or 
exposed jawbone with progression to sequestrum formation, 
localized swelling, and purulent discharge. Multiple affected 
sites are frequent. (14) Laboratory analysis reveals normal 
oral-cavity flora and Actimomyces as the most commonly 
isolated organisms in the oral cavity of  these patients. 
Radiographs routinely showed regions of  mottled bone, 
due to sequestrum formation. (15) Tissue biopsy should 
be performed only if  metastatic disease is suspected. In 
our patients, osteolysis consistent with bone loss could be 
observed in every orthopantomography.
To date, more than 200 cases of ONJ have been published since 
2003, most often in multiple myeloma and breast cancer. (16) 
One of the first attempts to determine the incidence of ONJ 
was reported by Durie et al; the authors performed a web-based 
survey of 1203 patients with multiple myeloma and breast cancer 
receiving bisphosphonates and found an incidence of 12,9% 
(152/1203). (7) This series has been criticized, however, because it 
used an open, uncontrolled questionnaire that physicians could 
answer for their patients, and because the study included patients 
with either confirmed or only suspected ONJ.  In another sma-
ller but prospective study by Bamias et al, the global incidence 
of osteonecrosis of the jaw was found to be 6,7%  (17/252) for 
the whole sample;  9,9% of patients with multiple myeloma, 
2,9% with breast cancer, and 6,5% with prostate cancer. (11) 
We reported here three cases of ONJ in patients with prostate 
adenocarcinoma that received zoledronic acid in 2005 at our 
hospital. Our incidence in this period was near 3% (3/104).
Fig. 3. Axial CT scan showing a diffuse osteonecrotic process 
involving part of the mandible, with gross bone destruction 
and an extensive periosteal reaction (case 3).
Fig. 4. Orthopantomography of the ONJ developed in case 3. (left side).
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CASE 1 CASE 2 CASE 3 
AGE 60 68 70 
RADIOTHERAPY Retroperitoneal Vertebral colapses Radical intention on prostate 
CHEMOTHERAPY
Stramustine. 
Docetaxel + prednisone. 
Vinorelbine. 
Docetaxel + stramustine. 
Prednisone.






YES YES NO 
DESNUTRITION Slight Moderate Slight 
TEETH INFECTION NO YES YES 
CICLES OF 
BIFOSFONATES 








Maximun serum creatinine 
level of 1,5 
NO
Maximun serum creatinine  
level of  1,45 
Assessment of dental status before treatment with bisphosphonates  
Close monitoring of oral hygiene 
Avoid invasive dental procedures during the treatment with bisphosphonates 
Follow-up patients being treated with bisphosphonates during more than two years  
Table 1. Main characteristics of the three clinical cases reported. 
Table 2. Several suggested recommendations to prevent ONJ related to biphosphonates 
employment.
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Moreover, these studies assessed the characteristics and risk 
factors for the development of ONJ in patients treated with 
bisphosphonates. Among these, the duration of treatment 
and number of infusions were strongly associated, implica-
ting drug exposure as the most significant risk factor for the 
development of osteonecrosis. In the study conducted by 
Bamias et al, no patients received fewer than 13 treatments, 
with a median of 35 infusions (range 13 to 68 infusions) 
(11). Our patients were also heavily exposed to zoledronic 
acid with a mean of 11,3 courses.
The type of bisphosphonate may play a role in the develo-
pment of ONJ.  For instance, some studies have observed 
fewer incidences of ONJ with pamidronate alone, indicating 
that osteonecrosis might occur earlier in treatment with 
zoledronic acid. (7, 17, 18) The reason for this difference 
remains unknown, but one possible explanation is that 
zoledronate has a more potent inhibitory effect on bone 
turnover than pamidronate. (11) 
On the other hand, it has been postulated that dental 
procedures may be an initiator factor for ONJ. In Bamias 
et al, 88% of patients had been subjected to either dental 
extraction within the year or had dentures preceding ONJ 
diagnosis. (11) In parallel, two patients from our series had 
suffered from dental procedures in the previous year.
Treatment of  patients with bisphosphonates-related 
osteonecrosis remains extremely difficult. Cessation of 
treatment could be considered in severe cases, but this 
option has not been shown to improve patient condition. 
Conservative therapy with antibiotics and mouth rinses is 
advocated, but a small percentage of patients require sur-
gery, which can range from simple debridement or curettage 
to radical resection depending on the extent of necrosis. 
(19) Serious caution must be exercised when contemplating 
surgery, however, as it is possible to exacerbate the avascular 
process and worsen the patient’s condition.  In our series, 
one of our patients required curettage while we were able 
to manage the others with more conservative approaches. 
Other approaches such as hyperbaric oxygen therapy have 
not shown positive results. (12, 20, 21)           
There are several ways to prevent osteonecrosis of the jaw 
in relation to the use of bisphosphonates, shown in table 2. 
Collaborations between medical oncologists and dentists 
are essential in order to minimize the morbidity of bisphos-
phonate-associated osteonecrosis. (17, 22, 23)
In conclusion, zoledronic acid is the most effective biphospho-
nate in preventing skeletal related events, particularly bone 
pain in bone metastatic cancer patients. Unfortunately ONJ 
has emerged as a severe complication for patients undergoing a 
heavy treatment regimen. Although published literature on this 
issue is sparse, physicians should be alert to patients with multiple 
biphosphonate  therapies and/or those with a particular type of 
dental history. The evidence linking bisphosphonates to ONJ 
is considered as level V evidence (evidence that is provided only 
from case reports and clinical examples); prospective clinical 
trials are imperative in order to evaluate the true frequency of 
bisphosphonate-related ONJ and to establish the causal factors 
related to its incidence in cancer patients. (24)
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